Targeted therapies in advanced differentiated thyroid cancer.

Raquel M Carneiro, Benedito A Carneiro, Mark Agulnik, Peter A Kopp, Francis J Giles

Journal: Cancer treatment reviews 2015;41(8):690-8

PMID: 26105190

Full Text on Elsevier Science View on PubMed

Abstract

Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, there was no effective therapy for these patients. With increasing knowledge of the molecular pathogenesis of thyroid cancer, novel targeted therapies are being developed for this group of patients. Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively. This represents a major innovation in the therapy of patients with advanced thyroid cancer. However, these therapies still have many limitations and further research needs to be pursued with the ultimate goal of providing safe and effective personalized therapy for patients with advanced thyroid cancer.

Address: Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, United States; Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address: [email protected].; Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, United States; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address: [email protected].; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address: [email protected].; Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address: [email protected].; Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, United States; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States. Electronic address: [email protected].

DOI: 10.1016/j.ctrv.2015.06.002

Link outs

Free resources

Medical:

https://medlineplus.gov/thyroidcancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Humans, Molecular Targeted Therapy, Neoplasm Staging, Niacinamide, Outcome Assessment, Health Care, Phenylurea Compounds, Quinolines, Receptors, Vascular Endothelial Growth Factor, Sorafenib, Thyroid Neoplasms, raf Kinases